Home › Amarantus Receives Orphan Drug Designation For Eltoprazine
 

Keywords :   


Amarantus Receives Orphan Drug Designation For Eltoprazine

2016-02-11 06:24:55| drugdiscoveryonline News Articles

Amarantus BioScience Holdings, Inc.(OTCQB: AMBS),a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced that it has received orphan drug designation from the US FDA for Eltoprazine in the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID).

Tags: drug receives designation orphan

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
07.11Amino updates Android STB portfolio with Amigo 7Y launch
07.11Sainsbury's and M&S warn Budget may push up prices
07.11VIZIO reports Q3 2024 financial results
07.11Farm Progress America, Nov. 7, 2024
07.11NanoTech Materials Named to TIMEs List of the Best Inventions of 2024
07.11Farm Progress America, Nov. 7, 2024
07.11ORF and ORS extend contract with SES at 19.2° East
07.11Victory+ to monetize over 60 new FAST channels with Amagi
More »